Hepatocyte Growth Factor and 10-Year Change in Left Ventricular Structure: The Multi-Ethnic Study of Atherosclerosis (MESA)

• Type of Material: Article
• Authors: Richard Ferraro, Johns Hopkins School of Medicine; Oluseye Ogunmoroti, Johns Hopkins School of Medicine; Di Zhao, Johns Hopkins Bloomberg School of Public Health; Chiadi E Ndumele, Johns Hopkins School of Medicine; Joao AC Lima, Johns Hopkins School of Medicine; Vinithra Varadarajan, Johns Hopkins School of Medicine; Vinita Subramanya, Emory University; Ambarish Pandey, UT Southwestern Medical Center; Nicholas B Larson, Mayo Medical School; Suzette J Bielinski, Mayo Medical School; Erin D Michos, Johns Hopkins School of Medicine
• Language: English
• Date: 2023-05-01
• Publisher: Elsevier Inc
• Publication Version: Final Published Version
• Copyright Statement: © 2023 The Authors
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.cjco.2023.02.004
• Title of Journal or Parent Work: CJC Open
• Volume: 5
• Issue: 5
• Start Page: 364
• End Page: 372
• Keywords: software impact
• Research Categories: Health Sciences, Public Health; Health Sciences, Pharmacology

Abstract

Background: Hepatocyte growth factor (HGF) is a cytokine linked to incident heart failure (HF), particularly HF with preserved ejection fraction (HFpEF). Increases in left ventricular (LV) mass and concentric remodelling defined by increasing mass-to-volume (M:V) ratios are imaging risk markers for HFpEF. We aimed to determine if HGF is associated with adverse LV remodelling. Methods: We studied 4907 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), free of cardiovascular disease and HF at baseline, who had HGF measured and cardiac magnetic resonance imaging (CMR) performed at baseline. Of these, 2921 completed a second CMR at 10 years. We examined the cross-sectional and longitudinal associations of HGF and LV structural parameters using multivariable-adjusted linear mixed-effect models, adjusting for cardiovascular disease risk factors and N-terminal pro B-type natriuretic peptide. Results: The mean (SD) for age was 62 (10) years; 52% were female. Median (interquartile range) for HGF level was 890 pg/mL (745-1070). At baseline, the highest HGF tertile, compared to the lowest, was associated with a greater M:V ratio (relative difference 1.94 [95% confidence interval [CI]: 0.72, 3.17]) and lower LV end-diastolic volume (–2.07 mL [95% CI: –3.72, –0.42)]. In longitudinal analysis, the highest HGF tertile was associated with increasing M:V ratio (10-year difference: 4.68 [95% CI: 2.64, 6.72]) and decreasing LV end-diastolic volume (–4.74 [95% CI: –6.87, –2.62]). Conclusions: In a community-based cohort, higher HGF levels were independently associated with a concentric LV remodelling pattern of increasing M:V ratio and decreasing LV end-diastolic volume by CMR over 10 years. These associations may reflect an intermediate phenotype explaining the association of HGF with HFpEF risk.